The role of expression of monocarboxylates of the first and fourth types (MCT1, MCT4) by tumor and stromal cells of prostate cancer in determining the prognosis and the efficiency of definitive treatment
- Autores: Vovdenko S.V1, Morozov A.O1, Avraamova S.T2, Aleksandrov N.S2, Zharkov N.V2, Saenko V.S1, Kogan E.A2, Bezrukov E.A1
-
Afiliações:
- Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University
- Institute of clinical morphology and digital pathology of FGAOU VO I.M. Sechenov First Moscow State Medical University
- Edição: Nº 5 (2022)
- Páginas: 64-70
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277124
- DOI: https://doi.org/10.18565/urology.2022.5.64-70
- ID: 277124
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
S. Vovdenko
Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: vovdenkostanislav@yandex.ru
Ph.D. student Moscow, Russia
A. Morozov
Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: andrei.o.morozov@gmail.com
senior researcher Moscow, Russia
S. Avraamova
Institute of clinical morphology and digital pathology of FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: avraamovast@mail.ru
Ph.D., assistant Moscow, Russia
N. Aleksandrov
Institute of clinical morphology and digital pathology of FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: dr.klauss@mail.ru
Ph.D., associate professor Moscow, Russia
N. Zharkov
Institute of clinical morphology and digital pathology of FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: nickzharkov@mail.ru
Ph.D. in Biology, senior assistant Moscow, Russia
V. Saenko
Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: saenko_vs@mail.ru
Ph.D., MD, professor Moscow, Russia
E. Kogan
Institute of clinical morphology and digital pathology of FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: koganevg@gmail.com
Ph.D., MD, professor Moscow, Russia
E. Bezrukov
Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University
Email: eabezrukov@rambler.ru
Ph.D., MD, professor Moscow, Russia
Bibliografia
- Loeb S. и др. Over diagnosis and over treatment of prostate cancer. EurUrol. Elsevier, 2014;65(6):1046-1055.
- Catalona W.J. Prostate Cancer Screening. Medical Clinics of North America. W.B. Saunders, 2018;102(2):199-214.
- Hanahan D., Weinberg R.A. Hallmarks of cancer: then extgeneration. Cell. Cell. 2011;144(5):646-674.
- Pertega-Gomes N. et al. Aglycolyticphenotype is associated with prostate cancer progression and aggressiveness: A role for monocarboxylate transporters as metabolic targets for therapy. J Pathol. John Wiley and Sons Ltd. 2015;236(4):517-530.
- Pertega-Gomes N., Baltazar F. Lactate transporters in the context of prostate cancer metabolism: What do we know? International Journal of Molecular Sciences. MDPI AG, 2014;15(10):18333-18348.
- Costello L.C. et al. Role of zinc in the pathogenesis and treatment of prostate cancer: Critical issues to resolve. Prostate Cancer Prostatic Dis. Prostate Cancer Prostatic Dis, 2004;7(2):111-117.
- Costello L.C., Franklin R.B., Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion. Mitochondrion. 2005;5,(3): 143-153.
- Pertega-Gomes N., Baltazar F. Lactate transporters in the context of prostate cancer metabolism: What do we know? International Journal of Molecular Sciences. MDPI AG, 2014;15(10):18333-18348.
- Franklin R.B., Costello L.C. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys. 2007;463(2): 211-217.
- Franz M.C. et al. Zinc transporters in prostate cancer. Molecular Aspects of Medicine. Mol Aspects Med. 2013;34(2-3):735-741.
- Fraum T.J. et al. Prostate cancer PET tracers: Essentials for the urologist. Can J Urol. 2018;25(4):9371-9383.
- Elia I. et al. Organ-specific cancer metabolism and its potential for therapy. Handbook of Experimental Pharmacology. Springer New York LLC. 2016;233:321-353.
- Hao J. et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br. J. Cancer. 2010; 103(7): 1008-1018.
- Pertega-Gomes N. идр. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. BioMed Central Ltd., 2011;11.
- Fiaschi T. et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. Cancer Res. 2012;72(19):5130-5140.
- Sanita P. et al. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer. BMC Cancer. 2014;14(1).
- Pertega-Gomes N. et al. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer. BioMed Central Ltd., 2014;14(1).
Arquivos suplementares
![](/img/style/loading.gif)